{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:33Z","timestamp":1786982133594,"version":"build-2736575974"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific Research Development Fund of Capital Medical University","award":["PYZ23140"],"award-info":[{"award-number":["PYZ23140"]}]},{"name":"Sanbo Brain Hospital Management Group","award":["SBJT-KY-2020\u2013002"],"award-info":[{"award-number":["SBJT-KY-2020\u2013002"]}]},{"name":"the Capital Health Research and Development Special Fund","award":["2022\u20132-8013"],"award-info":[{"award-number":["2022\u20132-8013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01731-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:42:27Z","timestamp":1765888947000},"page":"1537-1554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological Treatment for Adamantinomatous Craniopharyngioma"],"prefix":"10.1007","volume":"27","author":[{"given":"Chuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chingching","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"5","key":"1731_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrendo.2016.217","volume":"13","author":"HL M\u00fcller","year":"2017","unstructured":"M\u00fcller HL, Merchant TE, Puget S, Martinez-Barbera JP. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol. 2017;13(5):299\u2013312. https:\/\/doi.org\/10.1038\/nrendo.2016.217.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"1731_CR2","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1530\/eje-18-1021","volume":"180","author":"HL M\u00fcller","year":"2019","unstructured":"M\u00fcller HL. Management of endocrine disease: childhood-onset craniopharyngioma: state of the art of care in 2018. Eur J Endocrinol. 2019;180(4):R159\u2013 R1574. https:\/\/doi.org\/10.1530\/eje-18-1021","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1731_CR3","doi-asserted-by":"publisher","first-page":"e3820","DOI":"10.1210\/clinem\/dgab397","volume":"106","author":"A Otte","year":"2021","unstructured":"Otte A, M\u00fcller HL. Childhood-onset craniopharyngioma. J Clin Endocrinol Metab. 2021;106(10):e3820\u2013 e3836. https:\/\/doi.org\/10.1210\/clinem\/dgab397","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1731_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01468-7","volume":"20","author":"J He","year":"2021","unstructured":"He J, Zeng Z, Wang Y, Deng J, Tang X, Liu F, et al. Characterization of novel CTNNB1 mutation in craniopharyngioma by whole-genome sequencing. Mol Cancer. 2021;20(1):168. https:\/\/doi.org\/10.1186\/s12943-021-01468-7.","journal-title":"Mol Cancer"},{"issue":"8","key":"1731_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u2013 1251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"2","key":"1731_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109. https:\/\/doi.org\/10.1007\/s00401-007-0243-4.","journal-title":"Acta Neuropathol"},{"key":"1731_CR7","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/con.0000000000000536","volume":"23","author":"PY Wen","year":"2017","unstructured":"Wen PY, Huse JT. 2016 world health organization classification of central nervous system tumors. Continuum. 2017;23:1531\u2013 1547. https:\/\/doi.org\/10.1212\/con.0000000000000536","journal-title":"Continuum"},{"issue":"28","key":"1731_CR8","doi-asserted-by":"publisher","first-page":"11482","DOI":"10.1073\/pnas.1101553108","volume":"108","author":"C Gaston-Massuet","year":"2011","unstructured":"Gaston-Massuet C, Andoniadou CL, Signore M, Jayakody SA, Charolidi N, Kyeyune R, et al. Increased wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans. Proc Natl Acad Sci U S A. 2011;108(28):11482\u2013 11487. https:\/\/doi.org\/10.1073\/pnas.1101553108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"778","key":"1731_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn6763","volume":"16","author":"S Li","year":"2024","unstructured":"Li S, Li W, Miao Y, Gao M, Jia Y, Chen Z, et al. Modeling craniopharyngioma for drug screening reveals a neuronal mechanism for tumor growth. Sci Transl Med. 2024;16(778):eadn6763. https:\/\/doi.org\/10.1126\/scitranslmed.adn6763.","journal-title":"Sci Transl Med"},{"key":"1731_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae015","author":"EW Prince","year":"2024","unstructured":"Prince EW, Apps JR, Jeang J, Chee K, Medlin S, Jackson EM, et al. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multi-modal machine learning analysis. Neuro-Oncol. 2024. https:\/\/doi.org\/10.1093\/neuonc\/noae015.","journal-title":"Neuro-Oncol"},{"issue":"6","key":"1731_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.101188","volume":"11","author":"H Zhang","year":"2024","unstructured":"Zhang H, Wang C, Fan J, Guo R, Zhu Q, Pan J, et al. Factor analysis and subtyping significance of CTNNB1 gene mutation detection in adamantinomatous craniopharyngioma. Genes Dis. 2024;11(6):101188. https:\/\/doi.org\/10.1016\/j.gendis.2023.101188.","journal-title":"Genes Dis"},{"issue":"1","key":"1731_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01838-4","volume":"12","author":"JR Apps","year":"2024","unstructured":"Apps JR, Gonzalez-Meljem JM, Guiho R, Pickles JC, Prince E, Schwalbe E, et al. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression. Acta Neuropathol Commun. 2024;12(1):127. https:\/\/doi.org\/10.1186\/s40478-024-01838-4.","journal-title":"Acta Neuropathol Commun"},{"key":"1731_CR13","doi-asserted-by":"publisher","unstructured":"Piloni M, Gagliardi F, Bailo M, Losa M, Boari N, Spina A, et al. Craniopharyngioma in pediatrics and adults. Adv Exp Med Biol. 2023;1405(0). https:\/\/doi.org\/10.1007\/978-3-031-23705-8_11.","DOI":"10.1007\/978-3-031-23705-8_11"},{"issue":"6","key":"1731_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1055\/s-2004-832358","volume":"216","author":"M Warmuth-Metz","year":"2004","unstructured":"Warmuth-Metz M, Gnekow AK, M\u00fcller H, Solymosi L. Differential diagnosis of suprasellar tumors in children. Klin Padiatr. 2004;216(6):323\u2013330. https:\/\/doi.org\/10.1055\/s-2004-832358","journal-title":"Klin Padiatr"},{"key":"1731_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/cm9.0000000000002774","volume":"137","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao C, Lin J, Liu H, Zeng Q, Chen H, et al. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chin Med J. 2023;137:859\u2013 870. https:\/\/doi.org\/10.1097\/cm9.0000000000002774","journal-title":"Chin Med J"},{"issue":"1","key":"1731_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0125-9","volume":"5","author":"HL M\u00fcller","year":"2019","unstructured":"M\u00fcller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. https:\/\/doi.org\/10.1038\/s41572-019-0125-9.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1731_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng.2868","volume":"46","author":"PK Brastianos","year":"2014","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46(2):161\u2013165. https:\/\/doi.org\/10.1038\/ng.2868","journal-title":"Nat Genet"},{"issue":"1","key":"1731_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-025-01501-8","volume":"28","author":"NG Candy","year":"2025","unstructured":"Candy NG, Mignone E, Quick E, Koszyca B, Brown A, Chapman IM, et al. The role of BRAF testing of Rathke\u2019s cleft cysts to identify missed papillary craniopharyngioma. Pituitary. 2025;28(1):30. https:\/\/doi.org\/10.1007\/s11102-025-01501-8.","journal-title":"Pituitary"},{"issue":"6","key":"1731_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/nan.12226","volume":"41","author":"JP Martinez-Barbera","year":"2015","unstructured":"Martinez-Barbera JP. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma. Neuropathol Appl Neurobiol. 2015;41(6):721\u2013732. https:\/\/doi.org\/10.1111\/nan.12226","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"6","key":"1731_CR20","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.11981","volume":"25","author":"C Zhao","year":"2023","unstructured":"Zhao C, Hu W, Luo N, Wang X, Lin D, Lin Z. Expression of S100A9 in adamantinomatous craniopharyngioma and its association with wet keratin formation. Exp Ther Med. 2023;25(6):282. https:\/\/doi.org\/10.3892\/etm.2023.11981.","journal-title":"Exp Ther Med"},{"key":"1731_CR21","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.wneu.2022.05.115","volume":"165","author":"C Zhao","year":"2022","unstructured":"Zhao C, Zhou Z, Zhang Y, Qi X, Wang X, Lin D, et al. Diagnosis and management of pediatric papillary craniopharyngiomas. World Neurosurg. 2022;165:e148\u2013e158. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.115","journal-title":"World Neurosurg"},{"issue":"1","key":"1731_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-025-03238-1","volume":"48","author":"HJ Yoo","year":"2025","unstructured":"Yoo HJ, Ham CH, Roh H, Jo HJ, Kwon WK, Yoon W, et al. Radiosurgery versus radiation therapy for long term local control rate of craniopharyngioma: a meta-analysis. Neurosurg Rev. 2025;48(1):93. https:\/\/doi.org\/10.1007\/s10143-025-03238-1.","journal-title":"Neurosurg Rev"},{"key":"1731_CR23","doi-asserted-by":"publisher","DOI":"10.3171\/2024.9.Jns241482","author":"N Qiao","year":"2025","unstructured":"Qiao N, Li C, Zheng F, Zhang L, Yang X, Xu J, et al. Development and validation of a radiomics-visual evoked potential nomogram for preoperative prediction of visual outcome after endoscopic craniopharyngioma resection. J Neurosurg. 2025. https:\/\/doi.org\/10.3171\/2024.9.Jns241482.","journal-title":"J Neurosurg"},{"issue":"4","key":"1731_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00701-010-0940-y","volume":"153","author":"S Qi","year":"2011","unstructured":"Qi S, Lu Y, Pan J, Zhang X, Long H, Fan J. Anatomic relations of the arachnoidea around the pituitary stalk: relevance for surgical removal of craniopharyngiomas. Acta Neurochir. 2011;153(4):785\u2013796. https:\/\/doi.org\/10.1007\/s00701-010-0940-y","journal-title":"Acta Neurochir"},{"issue":"6","key":"1731_CR25","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3171\/jns.2008.109.12.1180","volume":"109","author":"JM Pascual","year":"2008","unstructured":"Pascual JM, Carrasco R, Prieto R, Gonzalez-Llanos F, Alvarez F, Roda JM. Craniopharyngioma classification. J Neurosurg. 2008;109(6):1180\u20131182. (author reply 1182-1183). https:\/\/doi.org\/10.3171\/jns.2008.109.12.1180","journal-title":"J Neurosurg"},{"issue":"4","key":"1731_CR26","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3171\/jns\/2008\/108\/4\/0715","volume":"108","author":"AB Kassam","year":"2008","unstructured":"Kassam AB, Gardner PA, Snyderman CH, Carrau RL, Mintz AH, Prevedello DM. Expanded endonasal approach, a fully endoscopic transnasal approach for the resection of midline suprasellar craniopharyngiomas: a new classification based on the infundibulum. J Neurosurg. 2008;108(4):715\u2013728. https:\/\/doi.org\/10.3171\/jns\/2008\/108\/4\/0715","journal-title":"J Neurosurg"},{"issue":"1","key":"1731_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/jns.1990.73.1.0003","volume":"73","author":"MG Ya\u015fargil","year":"1990","unstructured":"Ya\u015fargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg. 1990;73(1):3\u201311. https:\/\/doi.org\/10.3171\/jns.1990.73.1.0003.","journal-title":"J Neurosurg"},{"key":"1731_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.wneu.2017.02.095","volume":"102","author":"X Shi","year":"2017","unstructured":"Shi X, Zhou Z, Wu B, Zhang Y, Qian H, Sun Y, et al. Outcome of radical surgical resection for Craniopharyngioma with hypothalamic preservation: a single-center retrospective study of 1054 patients. World Neurosurg. 2017;102:167\u2013180. https:\/\/doi.org\/10.1016\/j.wneu.2017.02.095","journal-title":"World Neurosurg"},{"issue":"3","key":"1731_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1210\/endrev\/bnac035","volume":"44","author":"JR Apps","year":"2022","unstructured":"Apps JR, Muller HL, Hankinson TC, Yock TI, Martinez-Barbera JP. Contemporary biological insights and clinical management of craniopharyngioma. Endocr Rev. 2022;44(3):518\u2013538. https:\/\/doi.org\/10.1210\/endrev\/bnac035","journal-title":"Endocr Rev"},{"issue":"2","key":"1731_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.21873\/anticanres.13178","volume":"39","author":"TK Hill","year":"2019","unstructured":"Hill TK, Baine MJ, Verma V, Alam M, Lyden ER, Lin C, et al. Patterns of care in pediatric craniopharyngioma: outcomes following definitive radiotherapy. Anticancer Res. 2019;39(2):803\u2013807. https:\/\/doi.org\/10.21873\/anticanres.13178","journal-title":"Anticancer Res"},{"issue":"1","key":"1731_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00381-023-06088-8","volume":"40","author":"AR Tang","year":"2023","unstructured":"Tang AR, Haizel-Cobbina J, Khalid MU, Peter-Okaka UI, Prosak OL, Mushtaq N, et al. Global pediatric craniopharyngioma management modalities and outcomes. Childs Nerv Syst. 2023;40(1):47\u201356. https:\/\/doi.org\/10.1007\/s00381-023-06088-8.","journal-title":"Childs Nerv Syst"},{"key":"1731_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04925-7","author":"T Umeda","year":"2025","unstructured":"Umeda T, Otani Y, Fujii K, Ishida J, Hirano S, Suruga Y, et al. Identification of factors related to functional prognoses in craniopharyngiomas. J Neurooncol. 2025. https:\/\/doi.org\/10.1007\/s11060-024-04925-7.","journal-title":"J Neurooncol"},{"issue":"1","key":"1731_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00381-005-1171-z","volume":"22","author":"DK Gupta","year":"2006","unstructured":"Gupta DK, Ojha BK, Sarkar C, Mahapatra AK, Sharma BS, Mehta VS. Recurrence in pediatric craniopharyngiomas: analysis of clinical and histological features. Child\u2019s Nerv Syst: ChNS: Off J Int Soc Pediatr Neurosurg. 2006;22(1):50\u201355. https:\/\/doi.org\/10.1007\/s00381-005-1171-z","journal-title":"Child\u2019s Nerv Syst: ChNS: Off J Int Soc Pediatr Neurosurg"},{"key":"1731_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-013-0050-9","author":"N Karavitaki","year":"2014","unstructured":"Karavitaki N. Management of craniopharyngiomas. J Endocrinol Invest. 2014. https:\/\/doi.org\/10.1007\/s40618-013-0050-9.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"1731_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85262-1","volume":"15","author":"HL M\u00fcller","year":"2025","unstructured":"M\u00fcller HL, Witte J, Surmann B, Batram M, Braegelmann K, Flume M, et al. Treatment of patients with tumor\/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy. Sci Rep. 2025;15(1):2118. https:\/\/doi.org\/10.1038\/s41598-025-85262-1.","journal-title":"Sci Rep"},{"issue":"5","key":"1731_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/neuonc\/noz010","volume":"21","author":"VW Willard","year":"2019","unstructured":"Willard VW, Berlin KS, Conklin HM, Merchant TE. Trajectories of psychosocial and cognitive functioning in pediatric patients with brain tumors treated with radiation therapy. Neuro Oncol. 2019;21(5):678\u2013685. https:\/\/doi.org\/10.1093\/neuonc\/noz010","journal-title":"Neuro Oncol"},{"issue":"3","key":"1731_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-024-04621-6","volume":"167","author":"LB Palavani","year":"2024","unstructured":"Palavani LB, Silva GM, Borges PGLB, Ferreira MY, Sousa MP, Leite MGHSJ, et al. Fractionated stereotactic radiotherapy in craniopharyngiomas: a systematic review and single arm meta-analysis. J Neurooncol. 2024;167(3):373\u2013385. https:\/\/doi.org\/10.1007\/s11060-024-04621-6","journal-title":"J Neurooncol"},{"issue":"3","key":"1731_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11060-011-0693-3","volume":"106","author":"H Iwata","year":"2011","unstructured":"Iwata H, Tatewaki K, Inoue M, Yokota N, Baba Y, Nomura R, et al. Single and hypofractionated stereotactic radiotherapy with cyberknife for craniopharyngioma. J Neurooncol. 2011;106(3):571\u2013577. https:\/\/doi.org\/10.1007\/s11060-011-0693-3","journal-title":"J Neurooncol"},{"issue":"5","key":"1731_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135(5):757\u2013777. https:\/\/doi.org\/10.1007\/s00401-018-1830-2","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1731_CR40","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.cell.2020.10.044","volume":"183","author":"F Petralia","year":"2020","unstructured":"Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, et al. Integrated proteogenomic characterization across major histological types of pediatric brain cancer. Cell. 2020;183(7):1962-1985.e1931. https:\/\/doi.org\/10.1016\/j.cell.2020.10.044.","journal-title":"Cell"},{"issue":"4","key":"1731_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12795","volume":"48","author":"H Zhang","year":"2022","unstructured":"Zhang H, Wang C, Fan J, Zhu Q, Feng Y, Pan J, et al. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK\/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis. Neuropathol Appl Neurobiol. 2022;48(4):e12795. https:\/\/doi.org\/10.1111\/nan.12795.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"1731_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnen\/nlx061","volume":"76","author":"AM Donson","year":"2017","unstructured":"Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, et al. Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol. 2017;76(9):779\u2013788. https:\/\/doi.org\/10.1093\/jnen\/nlx061","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"1731_CR43","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00381-010-1245-4","volume":"26","author":"BL Pettorini","year":"2010","unstructured":"Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, et al. The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst. 2010;26(12):1779\u2013784. https:\/\/doi.org\/10.1007\/s00381-010-1245-4","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"1731_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020519","volume":"9","author":"R Whelan","year":"2020","unstructured":"Whelan R, Prince E, Gilani A, Hankinson T. The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med. 2020;9(2):519. https:\/\/doi.org\/10.3390\/jcm9020519.","journal-title":"J Clin Med"},{"issue":"8","key":"1731_CR45","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","volume":"20","author":"S Coy","year":"2018","unstructured":"Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, et al. Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro-Oncol. 2018;20(8):1101\u20131112. https:\/\/doi.org\/10.1093\/neuonc\/noy035","journal-title":"Neuro-Oncol"},{"issue":"1","key":"1731_CR46","doi-asserted-by":"publisher","DOI":"10.3171\/2019.10.Focus19705","volume":"48","author":"AC Hengartner","year":"2020","unstructured":"Hengartner AC, Prince E, Vijmasi T, Hankinson TC. Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus. 2020;48(1):E7. https:\/\/doi.org\/10.3171\/2019.10.Focus19705.","journal-title":"Neurosurg Focus"},{"key":"1731_CR47","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.wneu.2019.02.212","volume":"127","author":"D Lin","year":"2019","unstructured":"Lin D, Wang Y, Zhou Z, Lin Z. Immune microenvironment of primary and recurrent craniopharyngiomas: a study of the differences and clinical significance. World Neurosurg. 2019;127:e212\u2013e220. https:\/\/doi.org\/10.1016\/j.wneu.2019.02.212","journal-title":"World Neurosurg"},{"issue":"10","key":"1731_CR48","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1007\/s00018-021-03798-7","volume":"78","author":"JM Gonzalez-Meljem","year":"2021","unstructured":"Gonzalez-Meljem JM, Martinez-Barbera JP. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis. Cell Mol Life Sci. 2021;78(10):4521\u20134544. https:\/\/doi.org\/10.1007\/s00018-021-03798-7","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1731_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-024-01299-1","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Lin J, Liu H, Zhao C, Tu Z, Xu D, et al. Single-cell and spatial sequencing identifies senescent and germinal tumor cells in adamantinomatous craniopharyngiomas. Cell Biosci. 2024;14(1):112. https:\/\/doi.org\/10.1186\/s13578-024-01299-1.","journal-title":"Cell Biosci"},{"issue":"1","key":"1731_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01992-5","volume":"8","author":"JM Gonzalez-Meljem","year":"2017","unstructured":"Gonzalez-Meljem JM, Haston S, Carreno G, Apps JR, Pozzi S, Stache C, et al. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat Commun. 2017;8(1):1819. https:\/\/doi.org\/10.1038\/s41467-017-01992-5.","journal-title":"Nat Commun"},{"issue":"4","key":"1731_CR51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12672-010-0041-7","volume":"1","author":"ML Campanini","year":"2010","unstructured":"Campanini ML, Colli LM, Paixao BM, Cabral TP, Amaral FC, Machado HR, et al. CTNNB1 gene mutations, pituitary transcription factors, and microRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas. Horm Cancer. 2010;1(4):187\u2013196. https:\/\/doi.org\/10.1007\/s12672-010-0041-7","journal-title":"Horm Cancer"},{"issue":"9","key":"1731_CR52","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00381-016-3131-1","volume":"32","author":"J Samis","year":"2016","unstructured":"Samis J, Vanin EF, Sredni ST, de Bonaldo MDF, Costa FF, Tomita T, et al. Extensive miRNA expression analysis in craniopharyngiomas. Childs Nerv Syst. 2016;32(9):1617\u20131624. https:\/\/doi.org\/10.1007\/s00381-016-3131-1","journal-title":"Childs Nerv Syst"},{"key":"1731_CR53","doi-asserted-by":"publisher","unstructured":"Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89(0). https:\/\/doi.org\/10.1016\/j.biochi.2007.04.006.","DOI":"10.1016\/j.biochi.2007.04.006"},{"issue":"2","key":"1731_CR54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3171\/jns.2000.92.2.0255","volume":"92","author":"RI Jakacki","year":"2000","unstructured":"Jakacki RI, Cohen BH, Jamison C, Mathews VP, Arenson E, Longee DC, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg. 2000;92(2):255\u2013260. https:\/\/doi.org\/10.3171\/jns.2000.92.2.0255","journal-title":"J Neurosurg"},{"issue":"6","key":"1731_CR55","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3171\/2012.9.Peds12225","volume":"10","author":"JT Yeung","year":"2012","unstructured":"Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-\u03b1-2b for children with recurrent craniopharyngioma. J Neurosurg Pediatr. 2012;10(6):498\u2013503. https:\/\/doi.org\/10.3171\/2012.9.Peds12225.","journal-title":"J Neurosurg Pediatr"},{"issue":"11","key":"1731_CR56","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/neuonc\/noaa119","volume":"22","author":"S Goldman","year":"2020","unstructured":"Goldman S, Pollack IF, Jakacki RI, Billups CA, Poussaint TY, Adesina AM, et al. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a pediatric brain tumor consortium report. Neuro Oncol. 2020;22(11):1696\u20131704. https:\/\/doi.org\/10.1093\/neuonc\/noaa119","journal-title":"Neuro Oncol"},{"key":"1731_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00791","volume":"9","author":"S Grob","year":"2019","unstructured":"Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM, et al. Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma. Front Oncol. 2019;9:791. https:\/\/doi.org\/10.3389\/fonc.2019.00791.","journal-title":"Front Oncol"},{"key":"1731_CR58","doi-asserted-by":"publisher","unstructured":"de Vos-Kerkhof E, Buis DR, Lequin MH, Bennebroek CA, Aronica E, Hulleman E, et al. Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report. Front Endocrinol (Lausanne) 2023;14(0). https:\/\/doi.org\/10.3389\/fendo.2023.1225734.","DOI":"10.3389\/fendo.2023.1225734"},{"key":"1731_CR59","doi-asserted-by":"publisher","unstructured":"Webb LM, Okuno SH, Ransom RC, Van Gompel JJ, Humes AL, Sarkaria JN, et al. Recurrent adamantinomatous craniopharyngioma stabilized with tocilizumab and bevacizumab: illustrative case. J Neurosurg Case Lessons 2025;9(2). https:\/\/doi.org\/10.3171\/case24410.","DOI":"10.3171\/case24410"},{"issue":"1","key":"1731_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3171\/jns.1985.62.1.0120","volume":"62","author":"H Takahashi","year":"1985","unstructured":"Takahashi H, Nakazawa S, Shimura T. Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg. 1985;62(1):120. https:\/\/doi.org\/10.3171\/jns.1985.62.1.0120.","journal-title":"J Neurosurg"},{"key":"1731_CR61","unstructured":"Hargrave DR. Does chemotherapy have a role in the management of craniopharyngioma?. J Pediatr Endocrinol Metab. 2006:407\u2013412."},{"key":"1731_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00039","volume":"3","author":"U Bartels","year":"2012","unstructured":"Bartels U, Laperriere N, Bouffet E, Drake J. Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol. 2012;3:39. https:\/\/doi.org\/10.3389\/fendo.2012.00039.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1731_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000055955","volume":"33","author":"WJ Hader","year":"2000","unstructured":"Hader WJ, Steinbok P, Hukin J, Fryer C. Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg. 2000;33(4):211\u2013218. https:\/\/doi.org\/10.1159\/000055955","journal-title":"Pediatr Neurosurg"},{"issue":"6","key":"1731_CR64","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1130-1473(02)70576-9","volume":"13","author":"JF Alen","year":"2003","unstructured":"Alen JF, Boto GR, Lagares A, de La Lama A, Gomez PA, Lobato RD. Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature. Neurocirugia (Astur). 2003;13(6):479\u2013485.","journal-title":"Neurocirugia (Astur)"},{"key":"1731_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-005-1208-3","author":"H Takahashi","year":"2005","unstructured":"Takahashi H, Yamaguchi F, Teramoto A. Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children. Childs Nerv Syst. 2005. https:\/\/doi.org\/10.1007\/s00381-005-1208-3.","journal-title":"Childs Nerv Syst"},{"issue":"2","key":"1731_CR66","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2002.17.2.254","volume":"17","author":"DH Park","year":"2002","unstructured":"Park DH, Park JY, Kim JH, Chung YG, Lee HK, Lee KC, et al. Outcome of postoperative intratumoral bleomycin injection for cystic craniopharyngioma. J Korean Med Sci. 2002;17(2):254. https:\/\/doi.org\/10.3346\/jkms.2002.17.2.254.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1731_CR67","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clineuro.2006.09.002","volume":"109","author":"SD Kim","year":"2006","unstructured":"Kim SD, Park JY, Park J, Lee JB, Kim SH, Lim DJ. Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma. Clin Neurol Neurosurg. 2006;109(3):236\u2013241.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"1731_CR68","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3171\/jns.1996.84.1.0124","volume":"84","author":"S Cavalheiro","year":"1996","unstructured":"Cavalheiro S, Sparapani FV, Franco JO, da Silva MC, Braga FM. Use of bleomycin in intratumoral chemotherapy for cystic craniopharyngioma. Case report. J Neurosurg. 1996;84(1):124\u2013126. https:\/\/doi.org\/10.3171\/jns.1996.84.1.0124","journal-title":"J Neurosurg"},{"issue":"10","key":"1731_CR69","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/neuonc\/nox056","volume":"19","author":"JP Kilday","year":"2017","unstructured":"Kilday JP, Caldarelli M, Massimi L, Chen RH, Lee YY, Liang ML, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol. 2017;19(10):1398\u20131407. https:\/\/doi.org\/10.1093\/neuonc\/nox056","journal-title":"Neuro Oncol"},{"key":"1731_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1401761","volume":"14","author":"C Hedrich","year":"2024","unstructured":"Hedrich C, Patel P, Haider L, Taylor T, Lau E, Hook R, et al. Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma. Front Oncol. 2024;14:1401761. https:\/\/doi.org\/10.3389\/fonc.2024.1401761.","journal-title":"Front Oncol"},{"issue":"1","key":"1731_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29664-z","volume":"13","author":"C Zhao","year":"2023","unstructured":"Zhao C, Wang Y, Liu H, Qi X, Zhou Z, Wang X, et al. Molecular biological features of cyst wall of adamantinomatous craniopharyngioma. Sci Rep. 2023;13(1):3049. https:\/\/doi.org\/10.1038\/s41598-023-29664-z.","journal-title":"Sci Rep"},{"issue":"15","key":"1731_CR72","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc8933","volume":"9","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Yang J, Liang R, Zan X, Fan R, Shan B, et al. Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma. Sci Adv. 2023;9(15):eadc8933. https:\/\/doi.org\/10.1126\/sciadv.adc8933.","journal-title":"Sci Adv"},{"issue":"7","key":"1731_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ph17070949","volume":"17","author":"A de Pellegars-Malhortie","year":"2024","unstructured":"de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Pr\u00e9vostel C. Why is Wnt\/\u03b2-catenin not yet targeted in routine cancer care? Pharmaceuticals (Basel). 2024;17(7):949. https:\/\/doi.org\/10.3390\/ph17070949.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"1731_CR74","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/stem.3084","volume":"37","author":"L Preisler","year":"2019","unstructured":"Preisler L, Ben-Yosef D, Mayshar Y. Adenomatous polyposis coli as a major regulator of human embryonic stem cells self-renewal. Stem Cells. 2019;37(12):1505\u2013 515. https:\/\/doi.org\/10.1002\/stem.3084","journal-title":"Stem Cells"},{"issue":"7413","key":"1731_CR75","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nature11308","volume":"488","author":"BK Koo","year":"2012","unstructured":"Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012;488(7413):665\u2013669. https:\/\/doi.org\/10.1038\/nature11308","journal-title":"Nature"},{"issue":"3","key":"1731_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28753","volume":"68","author":"K Patel","year":"2021","unstructured":"Patel K, Allen J, Zagzag D, Wisoff J, Radmanesh A, Gindin T, et al. Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma. Pediatr Blood Cancer. 2021;68(3):e28753. https:\/\/doi.org\/10.1002\/pbc.28753.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"1731_CR77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/erc-18-0538","volume":"26","author":"G Carreno","year":"2019","unstructured":"Carreno G, Boult JKR, Apps J, Gonzalez-Meljem JM, Haston S, Guiho R, et al. Shh pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. Endocr Relat Cancer. 2019;26(3):355\u2013366. https:\/\/doi.org\/10.1530\/erc-18-0538","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1731_CR78","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.10281","volume":"94","author":"S Vidal","year":"2002","unstructured":"Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 2002;94(3):738\u2013745. https:\/\/doi.org\/10.1002\/cncr.10281","journal-title":"Cancer"},{"issue":"4","key":"1731_CR79","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1385\/EP:16:4:355","volume":"16","author":"CM Dallago","year":"2006","unstructured":"Dallago CM, Oliveira MC, Barbosa-Coutinho LM, Ferreira NP. Angiogenesis in craniopharyngiomas: microvascular density and tissue expression of the vascular endothelial growth factor (VEGF) and endostatin. Endocr Pathol. 2006;16(4):355\u2013362.","journal-title":"Endocr Pathol"},{"key":"1731_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.surneu.2006.05.047","author":"J Xu","year":"2006","unstructured":"Xu J, Zhang S, You C, Wang X, Zhou Q. Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol. 2006. https:\/\/doi.org\/10.1016\/j.surneu.2006.05.047.","journal-title":"Surg Neurol"},{"issue":"4","key":"1731_CR81","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1227\/01.Neu.0000367553.65099.14","volume":"66","author":"HI Sun","year":"2010","unstructured":"Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery. 2010;66(4):744\u2013750. https:\/\/doi.org\/10.1227\/01.Neu.0000367553.65099.14","journal-title":"Neurosurgery"},{"issue":"12","key":"1731_CR82","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1007\/s11064-011-0560-9","volume":"36","author":"Z Xia","year":"2011","unstructured":"Xia Z, Liu W, Li S, Jia G, Zhang Y, Li C, et al. Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma. Neurochem Res. 2011;36(12):2346\u20132351. https:\/\/doi.org\/10.1007\/s11064-011-0560-9","journal-title":"Neurochem Res"},{"issue":"3","key":"1731_CR83","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/01913120500408018","volume":"30","author":"L Agozzino","year":"2006","unstructured":"Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L. Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol. 2006;30(3):143\u2013150. https:\/\/doi.org\/10.1080\/01913120500408018","journal-title":"Ultrastruct Pathol"},{"issue":"3","key":"1731_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.14715\/cmb\/2024.70.3.20","volume":"70","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xu L, Ye J, Xu C, Wu B, Wu J, et al. Identification of core genes of craniopharyngioma angiogenesis based on single-cell nuclear transcriptome sequencing. Cell Mol Biol (Noisy-le-grand). 2024;70(3):136\u2013141. https:\/\/doi.org\/10.14715\/cmb\/2024.70.3.20","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"6","key":"1731_CR85","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ando.2023.10.003","volume":"84","author":"A De Rosa","year":"2023","unstructured":"De Rosa A, Calvanese F, Ducray F, Vasiljevic A, Manet R, Raverot G, et al. First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: case report and illustrative review. Ann Endocrinol (Paris). 2023;84(6):727\u2013733. https:\/\/doi.org\/10.1016\/j.ando.2023.10.003","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"1731_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11060-020-03578-6","volume":"149","author":"C Cacciotti","year":"2020","unstructured":"Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent\/refractory CNS tumors: a single institution experience. J Neuro-Oncol. 2020;149(1):113\u2013122. https:\/\/doi.org\/10.1007\/s11060-020-03578-6","journal-title":"J Neuro-Oncol"},{"key":"1731_CR87","doi-asserted-by":"publisher","unstructured":"Chen Y, Liu X, Ainiwan Y, Li M, Pan J, Chen Y, et al. Axl as a potential therapeutic target for adamantinomatous craniopharyngiomas: based on single nucleus RNA-seq and spatial transcriptome profiling. Cancer Lett. 2024;592(0). https:\/\/doi.org\/10.1016\/j.canlet.2024.216905.","DOI":"10.1016\/j.canlet.2024.216905"},{"issue":"10","key":"1731_CR88","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1159\/000539821","volume":"114","author":"W Li","year":"2024","unstructured":"Li W, Zhang Y, Zhuang Y, Chen R, Xiong Z, Li K, et al. Effects of simvastatin on inflammatory response and biological behaviour of adamantinomatous craniopharyngioma. Neuroendocrinology. 2024;114(10):934\u2013949. https:\/\/doi.org\/10.1159\/000539821","journal-title":"Neuroendocrinology"},{"issue":"1","key":"1731_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-024-09479-4","volume":"21","author":"H Deng","year":"2024","unstructured":"Deng H, Lei T, Liu S, Hao W, Hu M, Xiang X, et al. Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas. Clin Proteomics. 2024;21(1):29. https:\/\/doi.org\/10.1186\/s12014-024-09479-4.","journal-title":"Clin Proteomics"},{"issue":"2","key":"1731_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020723","volume":"25","author":"E Agosti","year":"2024","unstructured":"Agosti E, Zeppieri M, Antonietti S, Piazza A, Ius T, Fontanella MM, et al. Advancing craniopharyngioma management: a systematic review of current targeted therapies and future perspectives. Int J Mol Sci. 2024;25(2):723. https:\/\/doi.org\/10.3390\/ijms25020723.","journal-title":"Int J Mol Sci"},{"issue":"7262","key":"1731_CR91","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399\u2013401.","journal-title":"Nature"},{"issue":"4","key":"1731_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003444","volume":"9","author":"RC Ferreira","year":"2013","unstructured":"Ferreira RC, Freitag DF, Cutler AJ, Howson JM, Rainbow DB, Smyth DJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 2013;9(4):e1003444. https:\/\/doi.org\/10.1371\/journal.pgen.1003444.","journal-title":"PLoS Genet"},{"issue":"24","key":"1731_CR93","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1200\/jco.2006.08.8021","volume":"25","author":"WU Zhang","year":"2007","unstructured":"Zhang WU, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25(24):3712\u20133718. https:\/\/doi.org\/10.1200\/jco.2006.08.8021","journal-title":"J Clin Oncol"},{"issue":"7","key":"1731_CR94","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1470-2045(12)70231-0","volume":"13","author":"D Lambrechts","year":"2012","unstructured":"Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13(7):724\u2013733.","journal-title":"Lancet Oncol"},{"issue":"28","key":"1731_CR95","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1200\/jco.2008.16.1612","volume":"26","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26(28):4672\u20134678. https:\/\/doi.org\/10.1200\/jco.2008.16.1612","journal-title":"J Clin Oncol"},{"issue":"22","key":"1731_CR96","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1158\/1078-0432.Ccr-08-0351","volume":"14","author":"AM Schultheis","year":"2008","unstructured":"Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14(22):7554\u20137563. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-0351","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1731_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06104-1","volume":"151","author":"S Zhang","year":"2025","unstructured":"Zhang S, Xie B, He Y, Zhang X, Gong G, Li M, et al. Individual management and prognostic assessment for long-term outcomes using a novel classification system of craniopharyngiomas: a retrospective study of single institution. J Cancer Res Clin Oncol. 2025;151(2):57. https:\/\/doi.org\/10.1007\/s00432-025-06104-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1731_CR98","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/adc.75.2.108","volume":"75","author":"CJ DeVile","year":"1996","unstructured":"DeVile CJ, Grant DB, Hayward RD, Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child. 1996;75(2):108\u2013114. https:\/\/doi.org\/10.1136\/adc.75.2.108","journal-title":"Arch Dis Child"},{"key":"1731_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1274705","volume":"14","author":"M Schmutzer-Sondergeld","year":"2024","unstructured":"Schmutzer-Sondergeld M, Quach S, Niedermeyer S, Teske N, Ueberschaer M, Schichor C, et al. Risk-benefit analysis of surgical treatment strategies for cystic craniopharyngioma in children and adolescents. Front Oncol. 2024;14:1274705. https:\/\/doi.org\/10.3389\/fonc.2024.1274705.","journal-title":"Front Oncol"},{"issue":"3","key":"1731_CR100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3171\/2023.10.Peds23293","volume":"33","author":"M Caklili","year":"2024","unstructured":"Caklili M, Uzuner A, Yilmaz E, Duman Ozturk S, Cizmecioglu Jones FM, Balci S, et al. Surgical outcomes and follow-up results of 53 pediatric craniopharyngioma cases: a single-center study. J Neurosurg Pediatr. 2024;33(3):223\u201335. https:\/\/doi.org\/10.3171\/2023.10.Peds23293.","journal-title":"J Neurosurg Pediatr"},{"issue":"5","key":"1731_CR101","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3171\/2023.5.Peds22568","volume":"32","author":"OK Yousuf","year":"2023","unstructured":"Yousuf OK, Salehani A, Zimmerman K, Estevez-Ordonez D, Madura C, Arynchyna-Smith A, et al. Does subtotal resection ameliorate hypothalamic morbidity in pediatric craniopharyngioma? A 30-year retrospective cohort study. J Neurosurg Pediatr. 2023;32(5):569\u2013575. https:\/\/doi.org\/10.3171\/2023.5.Peds22568","journal-title":"J Neurosurg Pediatr"},{"issue":"12","key":"1731_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31343","volume":"71","author":"MR P\u00e9rez-Torres Lobato","year":"2024","unstructured":"P\u00e9rez-Torres Lobato MR, Morell M, Solano-P\u00e1ez P, Ortiz-Palacios M, Men\u00e1rgez \u00c1, Panesso M, et al. Long-term sequelae and quality of life after childhood-onset craniopharyngioma: results of a Spanish multicenter study. Pediatr Blood Cancer. 2024;71(12):e31343. https:\/\/doi.org\/10.1002\/pbc.31343.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1731_CR103","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1210\/clinem\/dgac678","volume":"108","author":"AH Shoemaker","year":"2022","unstructured":"Shoemaker AH, Tamaroff J. Approach to the patient with hypothalamic obesity. J Clin Endocrinol Metab. 2022;108(5):1236\u20131242.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1731_CR104","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/archpedi.156.9.887","volume":"156","author":"PW Mason","year":"2002","unstructured":"Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156(9):887\u2013892. https:\/\/doi.org\/10.1001\/archpedi.156.9.887","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"1731_CR105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000495851","volume":"12","author":"C Denzer","year":"2019","unstructured":"Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M. Treatment of hypothalamic obesity with dextroamphetamine: a case series. Obes Facts. 2019;12(1):91\u2013102. https:\/\/doi.org\/10.1159\/000495851.","journal-title":"Obes Facts"},{"key":"1731_CR106","doi-asserted-by":"publisher","unstructured":"Ismail D, O\u2019Connell MA, Zacharin MR. Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab. 2006;19(2). https:\/\/doi.org\/10.1515\/jpem.2006.19.2.129","DOI":"10.1515\/jpem.2006.19.2.129"},{"key":"1731_CR107","doi-asserted-by":"publisher","unstructured":"van Schaik J, Welling MS, de Groot CJ, van Eck JP, Juriaans A, Burghard M, et al. Dextroamphetamine treatment in children with hypothalamic obesity. Front Endocrinol (Lausanne). 2022;13(0). https:\/\/doi.org\/10.3389\/fendo.2022.845937.","DOI":"10.3389\/fendo.2022.845937"},{"key":"1731_CR108","doi-asserted-by":"publisher","unstructured":"Elfers CT, Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front Endocrinol (Lausanne). 2011;2(0). https:\/\/doi.org\/10.3389\/fendo.2011.00078.","DOI":"10.3389\/fendo.2011.00078"},{"issue":"7","key":"1731_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28379","volume":"67","author":"VE Horne","year":"2020","unstructured":"Horne VE, Bielamowicz K, Nguyen J, Hilsenbeck S, Lindsay H, Sonabend R, et al. Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020;67(7):e28379. https:\/\/doi.org\/10.1002\/pbc.28379.","journal-title":"Pediatr Blood Cancer"},{"key":"1731_CR110","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0022-3476(99)70017-X","volume":"135","author":"RH Lustig","year":"1999","unstructured":"Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr. 1999;135:162\u2013168.","journal-title":"J Pediatr"},{"issue":"6","key":"1731_CR111","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1210\/jc.2002-030003","volume":"88","author":"RH Lustig","year":"2003","unstructured":"Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586\u20132592. https:\/\/doi.org\/10.1210\/jc.2002-030003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1731_CR112","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000509302","volume":"13","author":"J van Schaik","year":"2020","unstructured":"van Schaik J, Begijn DGA, van Iersel L, Vergeer Y, Hoving EW, Peeters B, et al. Experiences with glucagon-like peptide-1 receptor agonist in children with acquired hypothalamic obesity. Obes Facts. 2020;13(4):361\u2013370. https:\/\/doi.org\/10.1159\/000509302","journal-title":"Obes Facts"},{"issue":"2","key":"1731_CR113","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/dom.14224","volume":"23","author":"CL Roth","year":"2021","unstructured":"Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, et al. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab. 2021;23(2):363\u2013373. https:\/\/doi.org\/10.1111\/dom.14224","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1731_CR114","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11102-024-01429-5","volume":"27","author":"M Svendstrup","year":"2024","unstructured":"Svendstrup M, Rasmussen AK, Kistorp C, Klose M, Andreassen M. Semaglutide treatment of hypothalamic obesity - a real-life data study. Pituitary. 2024;27(5):685\u2013692. https:\/\/doi.org\/10.1007\/s11102-024-01429-5","journal-title":"Pituitary"},{"issue":"5","key":"1731_CR115","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s11102-024-01426-8","volume":"27","author":"E Gjersdal","year":"2024","unstructured":"Gjersdal E, Larsen LB, Ettrup KS, Vestergaard P, Nielsen EH, Karmisholt JS, et al. Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma. Pituitary. 2024;27(5):723\u2013730. https:\/\/doi.org\/10.1007\/s11102-024-01426-8","journal-title":"Pituitary"},{"issue":"1","key":"1731_CR116","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/417949","volume":"2011","author":"JK Hamilton","year":"2011","unstructured":"Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic obesity following craniopharyngioma surgery: results of a pilot trial of combined diazoxide and metformin therapy. Int J Pediatr Endocrinol. 2011;2011(1):417949. https:\/\/doi.org\/10.1155\/2011\/417949.","journal-title":"Int J Pediatr Endocrinol"},{"key":"1731_CR117","doi-asserted-by":"publisher","unstructured":"Kalina MA, Wilczek M, Kalina-Faska B, Ska\u0142a-Zamorowska E, Mandera M, Ma\u0142ecka Tendera E. Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. J Pediatr Endocrinol Metab. 2014;28(0). https:\/\/doi.org\/10.1515\/jpem-2014-0425.","DOI":"10.1515\/jpem-2014-0425"},{"issue":"12","key":"1731_CR118","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1210\/jc.2016-2126","volume":"101","author":"R Brauner","year":"2016","unstructured":"Brauner R, Serreau R, Souberbielle JC, Pouillot M, Grouazel S, Recasens C, et al. Diazoxide in children with obesity after hypothalamic-pituitary lesions: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2016;101(12):4825\u20134833. https:\/\/doi.org\/10.1210\/jc.2016-2126","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1731_CR119","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/eje-12-0997","volume":"168","author":"F Zoicas","year":"2013","unstructured":"Zoicas F, Droste M, Mayr B, Buchfelder M, Sch\u00f6fl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168(5):699\u2013706. https:\/\/doi.org\/10.1530\/eje-12-0997.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1731_CR120","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/eje-21-0972","volume":"186","author":"K Huynh","year":"2022","unstructured":"Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687\u2013700. https:\/\/doi.org\/10.1530\/eje-21-0972.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1731_CR121","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/er.2009-0037","volume":"31","author":"YX Tao","year":"2010","unstructured":"Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010;31(4):506\u2013543. https:\/\/doi.org\/10.1210\/er.2009-0037","journal-title":"Endocr Rev"},{"issue":"10","key":"1731_CR122","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.peptides.2009.07.012","volume":"30","author":"KG Kumar","year":"2009","unstructured":"Kumar KG, Sutton GM, Dong JZ, Roubert P, Plas P, Halem HA, et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL\/6J mice. Peptides. 2009;30(10):1892\u20131900. https:\/\/doi.org\/10.1016\/j.peptides.2009.07.012","journal-title":"Peptides"},{"key":"1731_CR123","doi-asserted-by":"publisher","unstructured":"van Santen HM, Denzer C, M\u00fcller HL. Could setmelanotide be the game-changer for acquired hypothalamic obesity?. Front Endocrinol (Lausanne). 2024;14(0). https:\/\/doi.org\/10.3389\/fendo.2023.1307889.","DOI":"10.3389\/fendo.2023.1307889"},{"issue":"3","key":"1731_CR124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cne.10454","volume":"457","author":"T Kishi","year":"2003","unstructured":"Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol. 2003;457(3):213\u2013235. https:\/\/doi.org\/10.1002\/cne.10454","journal-title":"J Comp Neurol"},{"issue":"4","key":"1731_CR125","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2176\/nmc.41.210","volume":"41","author":"T Sadatomo","year":"2001","unstructured":"Sadatomo T, Sakoda K, Yamanaka M, Kutsuna M, Kurisu K. Mazindol administration improved hyperphagia after surgery for craniopharyngioma\u2013case report. Neurol Med Chir. 2001;41(4):210\u2013212. https:\/\/doi.org\/10.2176\/nmc.41.210","journal-title":"Neurol Med Chir"},{"key":"1731_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.704130","volume":"12","author":"F Yuan","year":"2021","unstructured":"Yuan F, Cai X, Zhu J, Yuan L, Wang Y, Tang C, et al. A novel immune classification for predicting immunotherapy responsiveness in patients with adamantinomatous craniopharyngioma. Front Neurol. 2021;12:704130. https:\/\/doi.org\/10.3389\/fneur.2021.704130.","journal-title":"Front Neurol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01731-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01731-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:24:41Z","timestamp":1766820281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01731-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":126,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01731-w","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All figures and tables in this manuscript are original creations by the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Inform Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}